Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Wintherix elects WX-04554 as lead drug for bone healing

Sep. 20, 2010

TransPharma completes phase Ia ViaDerm-GLP1 agonist trial

Sep. 17, 2010

Abbott responds to FDA advisory committee vote regarding sibutramine

Sep. 17, 2010

Lundbeck and Argenta disclose promising preclinical data on MCH1 receptor antagonists

Sep. 17, 2010

FDA approves Savient Pharmaceuticals' pegloticase for gout

Sep. 16, 2010

Galderma claims new inhibitors of ACAT-1

Sep. 16, 2010

Mimetica presents new modulators of melanocortin receptors

Sep. 15, 2010

Advinus Therapeutics discovers new molecule for diabetes type 2

Sep. 14, 2010

Ono Pharma and Astellas submit minodronic acid MAA in Japan for osteoporosis

Sep. 14, 2010

Merck Frosst Canada presents new acyl-CoA desaturase inhibitors

Sep. 13, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...